Cargando…

FGFR2–BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model

Epigenetic reprogramming is an independent mode of gene expression that often involves changes in the transcription and chromatin structure due to tumor initiation and development. In this study, we developed a specifically modified peptide array and searched for a recognized epigenetic reader. Our...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Josh Haipeng, Zhang, Lei, Wang, Zhenyi, Peltier, Raoul, Xie, Yusheng, Chen, Ganchao, Lin, Shiqi, Miao, Kai, Deng, Chu-Xia, Sun, Hongyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084888/ https://www.ncbi.nlm.nih.gov/pubmed/35547739 http://dx.doi.org/10.3389/fimmu.2022.861221

Ejemplares similares

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022)

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
por: Cerbelli, Bruna, et al.
Publicado: (2017)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

CDK5 Inhibition Abrogates TNBC Stem‐Cell Property and Enhances Anti‐PD‐1 Therapy
por: Bei, Yuncheng, et al.
Publicado: (2020)

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
por: Wu, Song-Yang, et al.
Publicado: (2022)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
por: Chen, Cunte, et al.
Publicado: (2021)

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression
por: Zhou, Julie Xia, et al.
Publicado: (2022)

Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
por: Harrasser, Micaela, et al.
Publicado: (2022)

Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
por: Ebine, Kazumi, et al.
Publicado: (2018)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

PB2476: TARGETING OF BRD4 TO COUNTERACT CYTOKINE-INDUCED EXPRESSION OF PD-L1 AND PD-L2 ON VASCULAR, OSTEOBLASTIC AND STROMAL NICHE CELLS
por: Filik, Yüksel, et al.
Publicado: (2023)

Unexpected PD‐L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies
por: Mondal, Tanmoy, et al.
Publicado: (2021)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells
por: Kim, Su-Lim, et al.
Publicado: (2023)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors
por: Toral, Keller J., et al.
Publicado: (2021)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension
por: Jiang, Lai, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
por: Englinger, Bernhard, et al.
Publicado: (2018)

The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1
por: Nguyen, P T, et al.
Publicado: (2013)

Synergy of Pd atoms and oxygen vacancies on In(2)O(3) for methane conversion under visible light
por: Luo, Lei, et al.
Publicado: (2022)

The Oncoprotein BRD4-NUT Generates Aberrant Histone Modification Patterns
por: Zee, Barry M., et al.
Publicado: (2016)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling
por: Glorieux, Christophe, et al.
Publicado: (2020)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models
por: Wu, Yinglin, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
por: Liu, Haoran, et al.
Publicado: (2020)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma
por: Shen, Bin, et al.
Publicado: (2019)

Pd(II) and Pt(II) Trinuclear Chelates with Spermidine: Selective Anticancer Activity towards TNBC-Sensitive and -Resistant to Cisplatin
por: Vojtek, Martin, et al.
Publicado: (2023)

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
por: Li, Yaqi, et al.
Publicado: (2016)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer
por: Jiang, Cui, et al.
Publicado: (2019)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pbosu9jvmpoac1pv3h98p9cmuf